The COMBINE TRIAL: Improving Treatment for Pediatric Crohn's Disease
About Us
- About PCORI
- The PCORI Strategic Plan
- Governance
- Evaluating Our Work
- PCORI's Advisory Panels
- Procurement Opportunities
-
Provide Input
-
Past Opportunities to Provide Input
- Stakeholder Views on Components of 'Patient-Centered Value' in Health and Health Care (2023)
- PCORI's Proposed Research Agenda (2021-2022)
- Proposed National Priorities for Health (2021)
- Proposed Principles for the Consideration of the Full Range of Outcomes Data in PCORI-Funded Research (2020)
- Proposed New PCORI Methodology Standards (2018)
- Data Access and Data Sharing Policy: Public Comment (2017)
- Proposed New PCORI Methodology Standards (2017)
-
Comment on the Proposed New and Revised PCORI Methodology Standards (2016)
- 1. Standards for Formulating Research Questions
- 10: Standards for Studies of Diagnostic Tests
- 12. Standards on Research Designs Using Clusters
- 13: General Comments on the Proposed Revisions to the PCORI Methodology Standards
- 2: Standards Associated with Patient-Centeredness
- 3: Standards for Data Integrity and Rigorous Analysis
- 4: Standards for Preventing and Handling Missing Data
- 5: Standards for Heterogeneity of Treatment Effects
- 6: Standards for Data Registries
- 7: Standards for Data Networks as Research-Facilitating Structures
- 8. Standards for Causal Inference Methods
- 9. Standards for Adaptive Trial Designs
- Peer-Review Process Comments (2014)
- Draft Methodology Report Public Comment Period (2012)
-
Past Opportunities to Provide Input
- Leadership
Image
Pediatric patients receiving the tumor necrosis factor (TNF) inhibitor adalimumab, combined with a low dose of methotrexate, a second immunosuppressant, to treat Crohn’s disease did better than those treated with adalimumab alone, according to findings of a PCORI-funded study published in Gastroenterology.
However, patients taking infliximab, another anti-TNF medication, had similar outcomes with or without methotrexate.
The results of The COMBINE Trial — led by Michael Kappelman, MD, MPH, from the School of Medicine at the University of North Carolina at Chapel Hill — provide important evidence to help answer questions about which medicines and combinations work best to treat Crohn’s disease in children. The lifelong inflammatory bowel disease is harder to treat in pediatric patients, but left untreated can impair growth, psychosocial development and puberty.
Posted: April 7, 2023
Tags
Recent Posts
What's Happening at PCORI?
The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.
Image
